DK1326634T3 - Vaccinepræparat der omfatter et antigen og et peptid med adjuvansegenskaber - Google Patents

Vaccinepræparat der omfatter et antigen og et peptid med adjuvansegenskaber

Info

Publication number
DK1326634T3
DK1326634T3 DK01980496T DK01980496T DK1326634T3 DK 1326634 T3 DK1326634 T3 DK 1326634T3 DK 01980496 T DK01980496 T DK 01980496T DK 01980496 T DK01980496 T DK 01980496T DK 1326634 T3 DK1326634 T3 DK 1326634T3
Authority
DK
Denmark
Prior art keywords
peptide
antigen
amino acid
acid residue
vaccine composition
Prior art date
Application number
DK01980496T
Other languages
Danish (da)
English (en)
Inventor
Joerg Fritz
Frank Mattner
Michael Buschle
Wolfgang Zauner
Eszter Nagy
Original Assignee
Intercell Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intercell Ag filed Critical Intercell Ag
Application granted granted Critical
Publication of DK1326634T3 publication Critical patent/DK1326634T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
DK01980496T 2000-10-18 2001-10-18 Vaccinepræparat der omfatter et antigen og et peptid med adjuvansegenskaber DK1326634T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AT0178900A AT410635B (de) 2000-10-18 2000-10-18 Vakzin-zusammensetzung

Publications (1)

Publication Number Publication Date
DK1326634T3 true DK1326634T3 (da) 2006-08-14

Family

ID=3688953

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01980496T DK1326634T3 (da) 2000-10-18 2001-10-18 Vaccinepræparat der omfatter et antigen og et peptid med adjuvansegenskaber

Country Status (27)

Country Link
US (3) US8361476B2 (pt)
EP (1) EP1326634B1 (pt)
JP (2) JP4227407B2 (pt)
KR (1) KR100598302B1 (pt)
CN (1) CN1248736C (pt)
AT (2) AT410635B (pt)
AU (2) AU2002212326B2 (pt)
BR (1) BRPI0114994B8 (pt)
CA (1) CA2426490C (pt)
CZ (1) CZ303303B6 (pt)
DE (1) DE60119145T2 (pt)
DK (1) DK1326634T3 (pt)
ES (1) ES2263668T3 (pt)
HK (1) HK1055899A1 (pt)
HU (1) HU228382B1 (pt)
IL (2) IL154605A0 (pt)
IS (1) IS2608B (pt)
MX (1) MXPA03002828A (pt)
NO (1) NO330274B1 (pt)
NZ (1) NZ524532A (pt)
PL (1) PL209016B1 (pt)
PT (1) PT1326634E (pt)
RU (2) RU2328305C2 (pt)
SI (1) SI1326634T1 (pt)
SK (1) SK287618B6 (pt)
WO (1) WO2002032451A1 (pt)
ZA (1) ZA200301465B (pt)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005004910A2 (en) * 2003-07-11 2005-01-20 Intercell Ag Hcv vaccines
AT410635B (de) * 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh Vakzin-zusammensetzung
WO2002053184A2 (en) * 2001-01-05 2002-07-11 Intercell Ag Uses for polycationic compounds as vaccine adjuvants
US7244438B2 (en) 2001-01-05 2007-07-17 Intercell Ag Uses for polycationic compounds
AT410798B (de) 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
EP1279404A1 (en) 2001-07-26 2003-01-29 Istituto Superiore di Sanità Use of HIV-1 tat, fragments or derivatives thereof, to target or to activate antigen-presenting cells, to deliver cargo molecules for vaccination or to treat other diseases
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
AU2003254585A1 (en) 2002-07-24 2004-02-16 Intercell Ag Antigens encoded by alternative reading frame from pathogenic viruses
US7785608B2 (en) 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
US7378234B2 (en) 2002-09-13 2008-05-27 Intercell Ag Method for isolating hepatitis C virus peptides
EP2314604A3 (en) 2002-10-15 2011-05-25 Intercell AG Nucleic acids coding for adhesion factors of group B streptococcus, adhesion factors of group B streptococcus and further uses thereof
DK1601770T3 (da) 2003-03-04 2009-11-02 Intercell Ag Streptococcus pyogenes antigener
ATE485056T1 (de) * 2003-03-24 2010-11-15 Intercell Ag Verbesserte impfstoffe
WO2004084937A1 (en) * 2003-03-24 2004-10-07 Intercell Ag Use of alum and a th1 immune response inducing adjuvant for enhancing immune responses
EP2182065A3 (en) 2003-03-31 2010-09-15 Intercell AG Staphylococcus epidermidis antigens
EP2298934A1 (en) 2003-04-15 2011-03-23 Intercell AG S. pneumoniae antigens
US8076059B2 (en) 2003-04-16 2011-12-13 Duke University Adjuvant capable of specifically activating the adaptive immune response
EP2275435A3 (en) 2003-05-07 2011-08-31 Intercell AG Streptococcus agalactiae antigens I + II
JP2008500007A (ja) 2003-05-30 2008-01-10 インターツェル・アクチェンゲゼルシャフト 腸球菌抗原
WO2005094891A2 (en) 2004-03-12 2005-10-13 Intercell Ag Method for solubilising peptide mixtures
ES2556710T3 (es) 2004-09-24 2016-01-19 Novartis Ag Proteínas capsidiales VP1 modificadas del parvovirus B19
EP2471550A1 (en) 2005-10-07 2012-07-04 Health Protection Agency Proteins with improved solubility and methods for producing and using same
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
ES2400531T3 (es) 2006-06-28 2013-04-10 Statens Serum Institut Expansión del repertorio de los linfocitos T para incluir epítopos subdominantes mediante vacunación con antígenos administrados en forma de fragmentos proteicos o cócteles peptídicos
JP2009542196A (ja) 2006-07-07 2009-12-03 インターセル アーゲー 小型の化膿連鎖球菌抗原およびそれらの使用
US8129165B2 (en) 2006-09-15 2012-03-06 Intercell Ag Borrelia antigens
EP1923069A1 (en) 2006-11-20 2008-05-21 Intercell AG Peptides protective against S. pneumoniae and compositions, methods and uses relating thereto
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
EP2269624A3 (en) 2007-01-12 2012-08-08 Intercell AG Protective proteins of S. agalactiae, combinations thereof and methods of using the same
US8236326B2 (en) 2007-05-02 2012-08-07 Intercell Ag Klebsiella antigens
EP2012122A1 (en) 2007-07-06 2009-01-07 Medigene AG Mutated parvovirus structural proteins as vaccines
US20100203083A1 (en) 2007-05-31 2010-08-12 Medigene Ag Mutated structural protein of a parvovirus
AU2008265218A1 (en) 2007-06-18 2008-12-24 Intercell Ag Chlamydia antigens
EP2265634A2 (en) 2008-03-17 2010-12-29 Intercell AG Peptides protective against s. pneumoniae and compositions, methods and uses relating thereto
EP2281574B1 (en) 2008-04-02 2014-07-09 The University of Tokushima Antigen-and-drug vehicle comprising synthetic peptide, and mucosal vaccine using the same
WO2009155484A2 (en) 2008-06-20 2009-12-23 Wyeth Compositions and methods of use of orf1358 from beta-hemolytic streptococcal strains
US20100015171A1 (en) * 2008-07-15 2010-01-21 Statens Serum Institute Vaccines comprising tb 10.4
WO2010089340A2 (en) 2009-02-05 2010-08-12 Intercell Ag Peptides protective against e. faecalis, methods and uses relating thereto
WO2010092176A2 (en) 2009-02-13 2010-08-19 Intercell Ag Nontypable haemophilus influenzae antigens
PT2445522T (pt) 2009-06-22 2017-10-04 Wyeth Llc Composições imunogénicas de antigénios de staphylococcus aureus
US9125951B2 (en) 2009-06-22 2015-09-08 Wyeth Llc Compositions and methods for preparing Staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
WO2011024071A1 (en) 2009-08-27 2011-03-03 Novartis Ag Adjuvant comprising aluminium, oligonucleotide and polycation
EP2308896A1 (en) 2009-10-09 2011-04-13 Sanofi-aventis Polypeptides for binding to the "receptor for advanced glycation endproducts" as well as compositions and methods involving the same
EP2319871A1 (en) 2009-11-05 2011-05-11 Sanofi-aventis Polypeptides for binding to the "receptor for advanced glycation endproducts" as well as compositions and methods involving the same
AU2010305374A1 (en) 2009-10-09 2012-05-03 Sanofi Polypeptides for binding to the "receptor for advanced glycation endproducts" as well as compositions and methods involving the same
US8765148B2 (en) 2010-02-19 2014-07-01 Valneva Austria Gmbh 1C31 nanoparticles
MX2012010609A (es) 2010-03-18 2012-10-03 Novartis Ag Vacunas adyuvadas para meningococos serogrupo b.
CN102933229A (zh) 2010-06-04 2013-02-13 惠氏有限责任公司 疫苗制剂
DK3246044T3 (da) 2010-08-23 2021-01-18 Wyeth Llc Stabile formuleringer af Neisseria-meningitidis-RLP2086-antigener
MX350126B (es) 2010-09-03 2017-08-28 Valneva Austria Gmbh Polipéptido aislado de las proteínas de la toxina a y la toxina b de c. difficile y usos del mismo.
AR082925A1 (es) 2010-09-08 2013-01-16 Medigene Ag Proteinas estructurales mutadas por parvovirus con epitopo de celulas b de proteccion cruzada, producto y metodos relacionados
EP3549601B1 (en) 2010-09-10 2021-02-24 Wyeth LLC Non-lipidated variants of neisseria meningitidis orf2086 antigens
PT2654784T (pt) 2010-12-22 2017-02-13 Wyeth Llc Composições imunogénicas estáveis de antigénios de staphylococcus aureus
BRPI1100857A2 (pt) * 2011-03-18 2013-05-21 Alexandre Eduardo Nowill agente imunomodulador e suas combinaÇÕes, seu uso e mÉtodo imunoterÁpico para a recontextualizaÇço, reprogramaÇço e reconduÇço do sistema imune em tempo real
ITMI20111182A1 (it) 2011-06-28 2012-12-29 Canio Buonavoglia Vaccino per coronavirus canino
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
SG10201602558UA (en) 2012-03-09 2016-05-30 Pfizer Neisseria meningitidis compositions and methods thereof
WO2013169922A1 (en) * 2012-05-08 2013-11-14 Western University Of Health Sciences Standardized ex vivo platforms for the antigen-specific expansion of cd4+ t cell populations
PT2911676T (pt) * 2012-10-29 2020-08-05 Univ Arkansas Adjuvantes das mucosas e sistemas de administração inovadores
SI3363806T1 (sl) 2012-12-20 2023-04-28 Pfizer Inc. Postopek glikokonjugacije
US9802987B2 (en) 2013-03-08 2017-10-31 Pfizer Inc. Immunogenic fusion polypeptides
US20140271723A1 (en) * 2013-03-15 2014-09-18 Saint Louis University Adjuvant compositions and methods of using thereof
KR20180099912A (ko) 2013-09-08 2018-09-05 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
WO2016130569A1 (en) 2015-02-09 2016-08-18 Mj Biologics, Inc. A composition comprising pedv antigens and methods for making and using the composition
CN107249626A (zh) 2015-02-19 2017-10-13 辉瑞大药厂 脑膜炎奈瑟球菌组合物及其方法
MX368897B (es) 2015-05-04 2019-10-21 Pfizer Conjugados proteina-polisacarido de estreptococo grupo b, metodos para producir conjugados, composiciones inmunogenas que comprenden conjugados y sus usos.
CN107446019B (zh) * 2016-07-01 2021-10-15 四川大学 抗菌肽衍生物及其用途
US10751402B2 (en) 2016-11-09 2020-08-25 Pfizer Inc. Immunogenic compositions and uses thereof
BR112019014397A2 (pt) 2017-01-31 2020-02-11 Pfizer Inc. Composições de neisseria meningitidis e métodos das mesmas
CN107266585B (zh) * 2017-07-13 2019-08-06 陕西科技大学 一种mlh融合抗菌肽及其制备方法和应用
JP2021513840A (ja) 2018-02-16 2021-06-03 ２エー ファーマ アーベー 自己免疫疾患の処置のためのパルボウイルス構造タンパク質
EP3527223A1 (en) 2018-02-16 2019-08-21 2A Pharma AB Mutated parvovirus structural protein
CN109745556A (zh) * 2019-03-01 2019-05-14 龙阔（苏州）生物工程有限公司 一种疫苗佐剂及其应用及猪繁殖与呼吸综合征疫苗
CN114127101A (zh) 2019-05-20 2022-03-01 瓦尔尼瓦公司 用于治疗或预防呼吸道感染的亚单位疫苗
WO2021202456A1 (en) * 2020-03-30 2021-10-07 The Wistar Institute Of Anatomy And Biology Synthetic soluble receptor mimics and methods of use for treatment of covid-19
WO2021211279A1 (en) 2020-04-17 2021-10-21 Regents Of The University Of Minnesota SARS-CoV-2 SPIKE RECEPTOR BINDING DOMAIN AND COMPOSITIONS AND METHODS THEREOF
WO2022043855A1 (en) 2020-08-26 2022-03-03 Pfizer Inc. Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
EP4319804A2 (en) 2021-04-09 2024-02-14 Valneva SE Human metapneumo virus vaccine
WO2023083964A1 (en) 2021-11-11 2023-05-19 2A Pharma Ab Parvovirus structural protein against beta- and gamma-hpv
WO2024069420A2 (en) 2022-09-29 2024-04-04 Pfizer Inc. Immunogenic compositions comprising an rsv f protein trimer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995004542A1 (en) * 1993-08-06 1995-02-16 Cytel Corporation Cloning and characterization of the complete mage-1 gene
JP3442824B2 (ja) * 1993-08-30 2003-09-02 理化学研究所 抗菌性ペプチド類
JP3547504B2 (ja) * 1994-11-01 2004-07-28 独立行政法人理化学研究所 新規なポリペプチド及びその用途
CA2293826A1 (en) 1997-06-11 1998-12-17 Brigitte Gicquel Attenuated recombinant mycobacteria useful as immunogens or as vaccine components
DK1009386T3 (da) 1997-08-29 2005-09-19 Corixa Corp Hurtigt-frigivende indkapslede bioaktive midler til at inducere eller potensere et immunrespons og fremgangsmåder til anvendelse deraf
CU22700A1 (es) * 1997-09-29 2001-07-31 Ct Ingenieria Genetica Biotech Formulación farmacéutica anti-viral que contiene un péptido de la proteína factor anti-lps de limulus y su uso
WO2005004910A2 (en) 2003-07-11 2005-01-20 Intercell Ag Hcv vaccines
US20020072495A1 (en) * 2000-09-21 2002-06-13 Oleg Chertov LL-37 is an immunostimulant
AT410635B (de) 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh Vakzin-zusammensetzung
ATE485056T1 (de) * 2003-03-24 2010-11-15 Intercell Ag Verbesserte impfstoffe
WO2004084937A1 (en) 2003-03-24 2004-10-07 Intercell Ag Use of alum and a th1 immune response inducing adjuvant for enhancing immune responses

Also Published As

Publication number Publication date
CZ303303B6 (cs) 2012-07-25
BRPI0114994B1 (pt) 2017-11-07
ZA200301465B (en) 2004-02-24
US20130216583A1 (en) 2013-08-22
BR0114994A (pt) 2003-09-30
AU1232602A (en) 2002-04-29
IL154605A (en) 2009-05-04
JP4227407B2 (ja) 2009-02-18
PL209016B1 (pl) 2011-07-29
IS2608B (is) 2010-04-15
IS6722A (is) 2003-02-20
WO2002032451A8 (en) 2002-05-23
CA2426490A1 (en) 2002-04-25
NO20031595L (no) 2003-06-05
ATA17892000A (de) 2002-11-15
US8361476B2 (en) 2013-01-29
CA2426490C (en) 2012-01-31
RU2007146372A (ru) 2009-06-20
KR100598302B1 (ko) 2006-07-07
SK287618B6 (sk) 2011-04-05
CZ20031299A3 (cs) 2003-10-15
JP2004511528A (ja) 2004-04-15
NO330274B1 (no) 2011-03-14
CN1248736C (zh) 2006-04-05
US20050063978A1 (en) 2005-03-24
KR20030043993A (ko) 2003-06-02
EP1326634B1 (en) 2006-04-26
PL362966A1 (en) 2004-11-02
HK1055899A1 (en) 2004-01-30
SI1326634T1 (sl) 2006-10-31
BRPI0114994B8 (pt) 2021-05-25
PT1326634E (pt) 2006-09-29
ES2263668T3 (es) 2006-12-16
AU2002212326B2 (en) 2006-01-05
EP1326634A1 (en) 2003-07-16
HU228382B1 (en) 2013-03-28
ATE324116T1 (de) 2006-05-15
AT410635B (de) 2003-06-25
SK5752003A3 (en) 2003-12-02
DE60119145D1 (de) 2006-06-01
WO2002032451A1 (en) 2002-04-25
MXPA03002828A (es) 2003-07-14
RU2328305C2 (ru) 2008-07-10
HUP0302117A2 (hu) 2003-09-29
IL154605A0 (en) 2003-09-17
HUP0302117A3 (en) 2004-11-29
DE60119145T2 (de) 2007-02-01
CN1468109A (zh) 2004-01-14
JP2008222721A (ja) 2008-09-25
NZ524532A (en) 2004-10-29
US8900564B2 (en) 2014-12-02
NO20031595D0 (no) 2003-04-08
US20090123486A1 (en) 2009-05-14

Similar Documents

Publication Publication Date Title
DK1326634T3 (da) Vaccinepræparat der omfatter et antigen og et peptid med adjuvansegenskaber
PL324531A1 (en) Derivatives of cyclosporin effective against hiv virus
RU2003114434A (ru) Вакцинная композиция
DE69940775D1 (de) Peptidzusammensetzung als immunogen zur allergiebehandlung.
ATE442378T1 (de) Substituierte wt1-peptide
ZA200207992B (en) Synthetic immunogenic but non-amyloidogenic peptides homologous to amyloid for induction of an immune response to amyloid and amyloid deposits.
ATE557041T1 (de) Peptid-vakzinen gegen streptokokken der gruppe a
PT1290013E (pt) Derivados dos peptidos apo-ai/aii
CY1108570T1 (el) Gd3-μιμητικα πεπτιδια
DE60144561D1 (de) N- und/oder c-terminal mit kurzen geladenen peptidsequenzen modifizierte peptide
BR0309491A (pt) Composição de vacina, composição imunogênica, utilização de uma proteìna e7 e anticorpos neutralizantes
SE9002684D0 (sv) New peptides and their use
ES2176334T3 (es) El uso de gabapentin en el tratamiento de la ansiedad y el panico.
MXPA02012664A (es) Peptidos para la preparacion de vacunas contra bordetella pertussis y bordetella parapertussis.
EA200100314A1 (ru) Пептидные фрагменты холерного экзотоксина в или энтеротоксина в в качестве адъювантов вакцины
WO1994004565A3 (en) Ipnv vaccine
WO2001074847A3 (en) T-cell epitope of mage-12 and related nucleic acids, vectors, cells, compositions and methods of inducing an immune response to cancer
AR009840A1 (es) Preparado vacunal para la inmunocastracion revesible de mamiferos
ECSP003720A (es) Peptidos modificados y peptidomimeticos para el uso en inmunoterapia
SE0002738D0 (sv) Electric actuator